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ABSTRACT
Objective: To describe hypocalcaemia due to vitamin D deficiency in ‘hikikomori’ syndrome.
Materials and methods: A 37-year-old man with ‘hikikomori’ syndrome for a year was admitted with hypocalcaemia (serum ionic calcium 1.17 
mmol/l). Serum 1,25(OH)
2
-vitamin D
3 
determined by liquid chromatography–tandem mass spectrometry was depressed at 12.1 pg/ml (29.0 
pmol/l) and plasma intact PTH elevated at 324 ng/l. Administration of 1 μg/day 1α(OH)-vitamin D
3
 and 1 g/day calcium lactate for 1 week 
normalized calcium and PTH, and raised 1,25(OH)
2
-vitamin D
3
 to low normal levels. 
Conclusion: This is the first report of hypocalcaemia due to vitamin D deficiency in a patient with ‘hikikomori’ syndrome. 
LEARNING POINTS
• A patient with psychiatric disorders can develop endocrine/metabolic abnormality.
• Hikikomori syndrome should be listed as a possible cause of hypocalcaemia in adults.
• Early diagnosis of hypocalcaemia in hikikomori syndrome prevents bone damage.
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CASE DESCRIPTION
‘Hikikomori’ syndrome has been described as complete withdrawal from society for 6 months or longer[1]. In the English version of Oxford 
Dictionaries, hikikomori is defined as (in Japan) the abnormal avoidance of social contact, typically by adolescent males. A person who avoids 
social contact. Origin: Japanese. literally “staying indoors, (social) withdrawal”. There are almost 1 million hikikomori in Japan between the 
ages of 20 and 40. Hikikomori syndrome[1, 2] is regarded as a mental or psychiatric disorder and most probably for this reason, metabolic 
abnormality, in particular hypocalcaemia, associated with this condition has not been described. 
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A 37-year-old man was admitted due to hypothermia and bizarre behaviour in mid-winter. He was found by his family unresponsive to verbal 
stimuli with rectal incontinence in his room without clothing or heating: the room temperature was 10°C. He had lived with his parents for 
about a year but rarely left his room, except for an occasional short walk at night. His past and family history was otherwise unremarkable 
except for his mother’s hypertension. 
Upon admission, his rectal temperature was 30.9°C, consciousness was Glasgow Coma Scale 3 (E1V1M1), blood pressure was 84/46 mmHg 
and pulse rate was 72/min, regular. His BMI was 20.5 kg/m2. There was generalized muscle weakness but Chvostek's and Trousseau's signs 
were negative. The patient had hypocalcaemia, as shown by an albumin-corrected serum calcium concentration (CSC) of 1.6 mmol/l, ionic 
calcium of 1.17 mmol/l (reference range, 1.21–1.36) and low urinary excretion of calcium of 0.009 mg/g creatinine (Table 1). ECG showed 
normal sinus rhythm and QTc was within the normal range at 0.416 sec. He also had hypoglycaemia, hypernatraemia and hyperkalaemia. 
Serum levels of hepatic enzymes except for γGTP were elevated; the serum alcohol concentration was not elevated. Renal function was also 
impaired (Table 1). Serum levels of vitamin B
12
 and folic acid were normal. Treatment with fluid and external warming was instituted, and 
the patient’s body temperature rose to 36.5°C within 6 hours and consciousness was normalized by day 2. Hypocalcaemia was investigated 
further.
Day 0 Day 2 Day 8 Day 15 Day 45
Serum chemistry 
Total protein, g/dl (6.7–8.3) 8.0 5.7 6.6
Albumin, g/dl (3.8–5.1) 4.9 3.0 2.7 3.0
Calcium, mg/dl (8.5–10.9) 7.1 6.4 8.3 8.8
CSC, mg/dl 6.2 9.3 10.1
Ionic calcium, mmol/l (1.21–1.36) 1.17
Phosphate, mg/dl (2.5–4.5) 4.7 4.4 4.9
Intact PTH, pg/ml (10–65) 324 30
AST, IU/l (11–39) 475 589 51 44 17
ALT, IU/l (5–43) 126 124 27 22 10
γGTP, IU/l (10–80) 28 17 36 63 28
LDH, IU/l (115–245) 664 1903 399 283 189
ALP, IU/l (105–320) 295 192 196 240 201
BUN, mg/dl (8–20) 46.0 41.3 10.6 8.3 8.6
Na, mEq/l (135–147) 149 139 138 138 140
K, mEq/l (3.4-4.8) 5.2 4.5 4.2 4.8 4.2
Scr, mg/dl (0.4–0.7) 3.53 2.9 0.74 0.72 0.69
eGFR, ml/min/1.73 m2 17.32 23.4 95.7 98.5 103.3
Alcohol, mg/ml <0.1
Bone ALP, μg/l (3.7–20.9) 7.7
NTX, nmol BCE/l 71.2
Random glucose, mg/dl 12 131 112 90 111
Insulin, μU/ml 8.2
HbA1c, % 4.8
Vitamin B
12
, pg/ml (180–914) 885
Folic acid, ng/ml (≥4.0) 5.2
Urine chemistry
Ca, mg/g creatinine 8.5 1.9
Phosphate, mg/dl 28.7 2.9
 Creatinine, mg/dl 35.0 42.0
%TRP 38.4 99
Table 1. General laboratory data 
ALP, alkaline phosphatase; ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; BCE/l, nmol bone collagen 
equivalents/l; BUN, blood urea nitrogen; CSC, albumin-corrected 
serum calcium; γGTP, gamma-glutamyl transpeptidase; eGFR, 
estimated glomerular filtration rate; LDH, lactate dehydrogenase; 
NTX, collagen type 1 cross-linked N-telopeptide; PTH, parathyroid 
hormone; Scr, serum creatinine; %TRP, percent tubular reabsorption 
of phosphate. 
Medications are described in the footnote of Table 2.
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Day 2 Day 8 Day 38 Day 45
LC-MS/MS
25(OH)-vitamin D
2
, ng/ml 0.29 0.32 0.10
25(OH)-vitamin D
3
, ng/ml 4.49 4.45 5.49
1,25(OH)2-vitamin D
3
, pg/ml 12.1 10.6 27.1
3-epi-25(OH)-vitamin D
3
, ng/ml 0.33 0.33 0.24
24,25(OH)
2
-vitamin D
3
, ng/ml 0.19 0.21 0.27
1,25(OH)
2
-vitamin D
2
, pg/ml <1.8 <1.8 <1.8
Radioimmunoassay
25(OH)-vitamin D (D
2
 and D
3
 combined), ng/ml 8.0 8.0
1,25(OH)
2
-vitamin D
3
, pg/ml 38.4 24.4
Initially, determination of 25(OH)-vitamin D (D
2
 and D
3
 combined) (Diasorin, Stillwater, MN), 1,25(OH)
2
-vitamin D
3
 (Immunodiagnostic 
Systems, Gaithersburg, MD) by radioimmunoassay (RIA) and intact parathyroid hormone (PTH) by electrochemiluminescence assay 
(Elecsys, Roche, Basel, Switzerland) was carried out at Special Reference Laboratories, Tokyo. Upon receiving an unexpectedly normal value 
for 1,25(OH)
2
-vitamin D
3 
(Table 2), serum levels of vitamin D and related molecules were re-determined by liquid chromatography–tandem 
mass spectrometry (LC-MS/MS) [3–5]. 
Serum concentrations of vitamin D and its precursors and metabolites are shown in Table 2. LC-MS/MS indicated that levels of vitamin D 
and its precursors and metabolites were all depressed, particularly 1,25(OH)
2
-vitamin D
3
. It should be noted that the values obtained by RIA 
for 25(OH)-vitamin D (D
2
 and D
3
 combined) and 1,25(OH)
2
-vitamin D
3
 were within the reference range. The plasma level of intact PTH was 
markedly elevated and urinary excretion of phosphate was elevated as indicated by low tubular reabsorption of phosphate. Bone alkaline 
phosphatase and collagen type 1 cross-linked N-telopeptide (NTX) were within the reference range (Table 2). 
Hypocalcaemia was diagnosed as caused by vitamin D deficiency arising from insufficient ultraviolet B irradiation due to hikikomori 
syndrome. Oral administration of 1 μg/day 1α(OH)-vitamin D
3
 and 1 g/day calcium lactate was begun. Treatment raised serum calcium levels 
within a week and normalized plasma intact PTH within 15 days (Table 2). At the same time, generalized muscle weakness disappeared. The 
plasma 1,25(OH)
2
-vitamin D
3
 level remained low at this stage but rose to the low normal range by day 45. 
DISCUSSION
Vitamin D deficiency in adults is not uncommon and frequently due to inadequate exposure to sunlight. Because of prolonged social 
withdrawal, patients with hikikomori syndrome may develop vitamin D deficiency due to inadequate exposure to sunlight. Nonetheless, 
hypocalcaemia and/or vitamin D deficiency has not previously been reported in hikikomori syndrome[1,2] and may have been overlooked. 
In fact, Chvostek's and/or Trousseau's signs were both negative in this case, and hypocalcaemia was found incidentally during the general 
laboratory investigation. The lifestyle of this patient was typical of ‘hikikomori’ syndrome in that he had no exposure to sunlight for about 
a year. Consequently, the pathophysiology of this patient was similar to rickets. Nonetheless, bone alkaline phosphatase and NTX were 
normal, indicating that bone turnover had not yet been depressed. 
Importantly, the RIA method commonly used to assess vitamin D and related molecules may not be reliable when levels are very low, as in 
this patient, since RIA overestimated vitamin D and a precursor molecule, as reported elsewhere. Therefore, RIA should not be relied on 
solely to diagnose vitamin D deficiency, with LC-MS/MS being a better choice[3–5].
In conclusion, we have described hypocalcaemia in ‘hikikomori’ syndrome arising vitamin D deficiency for the first time. Further studies are 
warranted to establish the prevalence and severity of hypocalcaemia and vitamin D deficiency in this syndrome. LC-MS/MS instead of RIA is 
recommended as the method to determine levels of vitamin D and its metabolites in order to assess vitamin D levels.
Table 2. Serum levels of vitamin D and related substances before 
and after treatment 
LC-MS/MS, liquid chromatography-tandem mass spectrometry.
Medications were as follows. 1α(OH)-Vitamin D3: 1 μg/day from day 
2 to day 15, 0.5 μg/day from day 16 to day 17, withdrawn from day 
18 to day 41, 0.25 μg/day from day 42, and on. Calcium lactate: 1 
g/day from day 2 to day 10, withdrawn from day 11 to day 34, 1 g/
day from day 35, and so on. Calcium carbonate: 1 g/day from day 
11 to day 34.
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